23.04.2021 Evotec SE  DE0005664809

DGAP-Adhoc: Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021


 

DGAP-Ad-hoc: Evotec SE / Key word(s): Miscellaneous
Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021

23-Apr-2021 / 13:03 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021

Hamburg, Germany - Evotec SE (Frankfurt Stock Exchange; EVT, MDAX/TecDAX, ISIN: DE0005664809, WKN 566480) announces that today the Chairman of the Supervisory Board, Prof. Dr Wolfgang Plischke, has informed the Company of his decision to resign from his office in the Supervisory Board of Evotec SE effective as of the end of the Annual General Meeting on 15 June 2021 due to personal reasons. Prof. Dr Plischke has been serving in the Supervisory Board as Chairman since 2014.

 

Contact:
Dr Werner Lanthaler, Chief Executive Officer

Evotec SE
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg, Germany

Phone: +49.(0)40.560 81-242
Email: [email protected]


23-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1187983

 
End of Announcement DGAP News Service

1187983  23-Apr-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1187983&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 257,63 375,41 446,44 500,92 618,03 751,45 835,00
EBITDA1,2 57,22 95,46 123,14 51,77 101,65 102,51 122,00
EBITDA-Marge3 22,21 25,43 27,58 10,33 16,45 13,64
EBIT1,4 37,50 77,46 62,59 48,52 41,00 20,85 0,00
EBIT-Marge5 14,56 20,63 14,02 9,69 6,63 2,78 0,00
Jahresüberschuss1 24,00 84,06 37,23 6,25 215,51 -175,66 0,00
Netto-Marge6 9,32 22,39 8,34 1,25 34,87 -23,38 0,00
Cashflow1,7 10,83 156,24 42,22 44,72 122,24 203,11 0,00
Ergebnis je Aktie8 0,16 0,46 0,25 0,04 1,30 -0,99 -0,50
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: BDO

INVESTOR-INFORMATIONEN
©boersengefluester.de
Evotec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
566480 13,260 Halten 2.354,21
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
19,50 34,95 0,56 74,92
KBV KCV KUV EV/EBITDA
2,06 11,59 3,13 23,84
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 10.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
22.05.2024 14.08.2024 08.11.2023 24.04.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-3,18% -25,40% -37,69% -23,77%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Evotec SE  ISIN: DE0005664809 können Sie bei EQS abrufen


Biotechnologie , 566480 , EVT , XETR:EVT